Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in research and development innovations, production and commercialization of life-saving vaccines based on viral vectors for the delivery of antigens targeting infectious diseases. Bavarian Nordic A/S offers travel health products including cholera, rabies, tick-borne encephalitis and typhoid vaccines, as well as vaccines sold and distributed in selected markets on behalf of third parties. The firm deals with vaccines aimed at improving public health and preparedness. Bavarian Nordic A/S focuses on vaccine solutions that help address the threat of infectious diseases. The firm operates worldwide.
Follow-Up Questions
Qui est le CEO de Bavarian Nordic A/S ?
Dr. Paul Chaplin est le President de Bavarian Nordic A/S, il a rejoint l'entreprise depuis 2014.
Quelle est la performance du prix de l'action BVNRY ?
Le prix actuel de BVNRY est de $12.06, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Bavarian Nordic A/S ?
Bavarian Nordic A/S appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Bavarian Nordic A/S ?
La capitalisation boursière actuelle de Bavarian Nordic A/S est de $956.0M
Est-ce que Bavarian Nordic A/S est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 5 analystes ont établi des notations d'analystes pour Bavarian Nordic A/S, y compris 2 achat fort, 4 achat, 2 maintien, 0 vente et 2 vente forte
